Some encouraging data is emerging, for example in a recent study, which assessed 7 patients transplanted with intravenous MSCs (1 × 106 per kg) and 3 patients in the placebo controlled group albeit consisting of all female patients, showed significant improvement in pulmonary function and symptoms as well as substantial reduction in inflammation compared to the placebo controlled group (Figure 2).